Prognostic Score in the Very Old ICU Patients (VIP2)

April 27, 2021 updated by: Hans Flaatten, University of Bergen

Development and Validation of a Prognostic Score in the Very Old ICU Patients (≥80 Years)

The two main aims of the study:

  1. To investigate the relation of Frailty, Activity of daily life (ADL), Cognitive functions and Co-morbidity on survival at 30 days (and 6 months in a substudy)
  2. From the results design a prognostic score that will be validated using a subpopulation of the study cohort

Two secondary aims a

  1. Survival at 6 months (in a subpopulation of the study)
  2. An inter-rater validation of the Clinical Frailty Score (CFS) (in a subpopulation)

Substudies are planned with regards to the different admission categories, in particular:

  • trauma
  • acute respiratory failure
  • sepsis
  • combined respiratory and circulatory failure
  • medical neurological conditions In some of the substudies similar groups from the VIP1 study that uses the same admission categories (except planned admissions) will be merged.

Study Overview

Status

Completed

Detailed Description

Frailty to be registered by the Clinical Frailty Scale (CFS), 1-9 point Activity of Daily life (ADL) with Katz ADL form: 0-6 points Cognition to be described by Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) questionaire, 16 questions to be asked the care-givers Co-morbidity by listing the major comorbidity with Yes or No (Yes= 1 point) and with the number of regular drugs prescribed

Study Type

Observational

Enrollment (Actual)

3900

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bergen, Norway, 5021
        • Haukeland University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

76 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Critical ill patients admitted to the ICU ≥ 80 years

Description

Inclusion Criteria:

  • ≥80 admitted to an ICU as an emergency case

Exclusion Criteria:

  • elective admissions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
30 days survival
Time Frame: 30 days
Proportion alive after 30 days
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Developement of a prognostic score
Time Frame: 6 months
Developement and subsequent validation of a prognostic score from data revealed in the study: Frailty, Comorbidity, Activity of Daily life and Cognition. This score is non-existent at the moment, it is a score we will develope and test within the cohort-. No further description can be given before study is finished and analysed.
6 months
6 months survival
Time Frame: 6 months
Proportion alive after 6 months
6 months
Inter-rater validation of Clinical Frailty Scale (CFS)
Time Frame: At admission
The CFS is a simple visual scale of frailty from 1 to 9 (increasing frailty). We will in a subset of our patients use two raters to perform frailty score and compare their results using inter-rater variability tests.
At admission

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survival analysis in pre-defined subgroups: Admission categories, use of therapeutic procedures, end-of-life desicion
Time Frame: Up to 6 months
Proportions alive after 30 days and 6 months
Up to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2018

Primary Completion (Actual)

November 1, 2019

Study Completion (Actual)

November 1, 2019

Study Registration Dates

First Submitted

December 7, 2017

First Submitted That Met QC Criteria

December 7, 2017

First Posted (Actual)

December 12, 2017

Study Record Updates

Last Update Posted (Actual)

April 28, 2021

Last Update Submitted That Met QC Criteria

April 27, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • VIP2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Care

Clinical Trials on Cognitive assesment, Frailty assessment

Subscribe